[HTML][HTML] Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer
Z Song, X Yu, C He, B Zhang… - Journal of Thoracic …, 2013 - ncbi.nlm.nih.gov
Objective Few treatment options are available for advanced non-small cell lung cancer
(NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line …
(NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line …
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer chemotherapy and …, 2010 - Springer
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
Salvage treatment with erlotinib after gefitinib failure in advanced non‐small‐cell lung cancer patients with poor performance status: A matched‐pair case–control …
D Luo, M Huang, X Zhang, M Yu, B Zou, Y Li… - Thoracic …, 2012 - Wiley Online Library
Purpose: Gefitinib plays an important role in non‐small‐cell lung cancer (NSCLC) treatment;
however, progression of the disease occurs in most patients even after an initial response …
however, progression of the disease occurs in most patients even after an initial response …
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection
A Hata, N Katakami, H Yoshioka, S Fujita, K Kunimasa… - Lung cancer, 2011 - Elsevier
BACKGROUND: Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
Z Song, Y Yu, Z Chen, S Lu - Chinese Medical Journal, 2011 - mednexus.org
Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …
[HTML][HTML] Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
Methods: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib
failure at Seoul National University Hospital between August 2005 and November 2011 …
failure at Seoul National University Hospital between August 2005 and November 2011 …
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
[HTML][HTML] Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer
R Maruyama, H Wataya, T Seto, Y Ichinose - Anticancer research, 2009 - ar.iiarjournals.org
Background: The optimal treatment for patients with progressive non-small cell lung cancer
who initially show a good response to gefitinib is unclear. Patients and Methods: This study …
who initially show a good response to gefitinib is unclear. Patients and Methods: This study …
相关搜索
- gefitinib failure salvage treatment
- gefitinib in patients failure of erlotinib
- lung cancer failure of erlotinib
- lung cancer administration of gefitinib
- gefitinib failure clinical efficacy
- erlotinib in patients previous chemotherapy
- gefitinib failure performance status
- lung cancer gefitinib in patients
- erlotinib in patients comparison of gefitinib
- gefitinib failure patient selection
- gefitinib failure clinical benefit